search
        Home > Projects > Cardiovascular diseases > Eminence    
Cancer
Cardiovascular diseases
Neurodegenerative diseases
Infection and immunity
Translational Research IT (TraIT)
 
 
 
EMINENCE Project
 
Principal Investigator Prof. Dr. M.J. Post (Maastricht University Medical Centre)
CTMM Program manager: Henny Bruinewoud
 
 
The lack of neovascularization in ischemic disease typically marks the fatal progression of these conditions as well as the transition between potential success and failure of therapy. Ample pre-clinical proof of concept for successful therapeutic intervention with subsequent improvement of blood perfusion has already been demonstrated. Despite this, effective translation of neovascularization therapy into high volume patient care has still not occurred, most probably due to the lack of sensitive methods for detecting neovascularization, inadequate techniques for patient selection and ineffective delivery platforms for growth factor based therapies.
 
The Eminence project aims to develop multiple diagnostic technologies to enable the early and sensitive detection of neovascularization, and novel tools to stratify an individual patient’s risk of cardiovascular disease. It will build on previous experience to develop multi-modal and multi-valent contrast agents suitable for combined platform imaging. To accelerate translation into clinical practice, the project will design protocols to synthesize molecular ligands and label them with radionuclide isotopes and/or ultra-small-iron-oxide particles for use in combined MRI and PET/SPECT imaging. In addition to these molecular imaging approaches, the project will aim to improve functional MR imaging in order to assess the perfusional consequences of neovascularization by optimizing flow measurements for small arteries and quantifying cardiac and skeletal muscle perfusion.
 
Potential applications include atherosclerosis, heart failure, cancer, chronic inflammation and diabetic complications such as diabetic retinopathy or diabetes associated vascular disease.
 
 

Professor Post - Mark Post.JPG

 
Prof. Mark J. Post:
“National and international support for the EMINENCE consortium, together with the BMM partner program PENT, will foster new diagnostic techniques to assess blood supply to the heart or legs, thereby facilitating development of therapies to improve that blood supply.”
 
 
Prof. Dr. Mark Post received his medical degree and PhD from the University of Utrecht. After a period at the KNAW Interuniversity Cardiology Institute of the Netherlands, he was appointed full time assistant professor in Medicine at Harvard Medical School, Boston (USA), where he continued research into neovascularization. He subsequently became associate professor of Medicine and Physiology at Dartmouth Medical School, Hanover (USA), later returning to the Netherlands as professor of Vascular Physiology at the Maastricht University and professor of Angiogenesis in Tissue Engineering at TU/e. He holds the Chair of Physiology and interim Chair of Biomedical Engineering at Maastricht University Medical Center and is vice dean of the Department of Biomedical Engineering at TU/e.
 
 
 
Industrial partners   
  • MiLabs BV
  • PIE Medical Imaging BV
 
 
Academic partners
  • Academisch Medisch Centrum (AMC)
  • Maastricht University Medical Center (MUMC+)
  • Universitair Medisch Centrum Utrecht (UMCU)

The CTMM Eminence project also receives additional contribution from the Netherlands Heart Foundation.

 
Status of the Eminence project end of 2009: PDF (download)
Eminence project presentation at the CTMM Annual Meeting 2010: PDF (download)
 
 
General
 
In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of 150 million Euro. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, will receive funding amounting to a total of almost another 100 million Euro.
 
All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM, and the Dutch Government are involved.
 
The funding is provided by the Dutch government, industry and academia. The research is focused firmly on the ‘translational’ aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.
 
Eminence is one of the projects from the second call.
 
 
26 November 2010
 
 
 
   
   
   


 
   

 

 

© CTMM, Center for Translational Molecular Medicine | Contact | Login | Disclaimer